What’s Going On With Best Buy Stock Today?
Best Buy Co Inc (NYSE: BBY) shares are trading higher Thursday after the company updated its second-quarter and full-year outlook.
Honeywell Gains On Strong Q2 Results; Beats Street Expectations
Honeywell International Inc (NASDAQ:HON) reported a second-quarter sales growth of 2% year-over-year to $8.95 billion, +4% on an organic basis,…
Canada-Based Project Solace Aims To Provide Access And Data On Medical Psilocybin
TheraPsil, a Canadian coalition for psilocybin therapy legalization, together with the U.K. independent foundation Drug Science, has launched Project Solace.
Hershey Sweetens FY22 Forecast On Q2 Earnings Beat
Hershey Co (NYSE:HSY) reported second-quarter FY22 sales growth of 19.3% year-on-year, to $2.37 billion, beating the consensus of $2.22 billion. Hershey’s…
Southwest Airlines Shares Slip Post Q2 Results, Foresees Lower Capacity in FY22, Slashes Boeing Aircraft Deliveries Estimates By 42%
Southwest Airlines Co (NYSE: LUV) reported second-quarter FY2
Marlboro Maker Altria Reaffirms FY22 Earnings Guidance Post Q2 Beat
Marlboro maker Altria Group Inc (NYSE:MO) reported a second-quarter FY22 sales decline of 5.7% year-on-year, to $6.54 billion, beating the consensus of…
Stanley Black & Decker Shares Plunge On Q2 Miss, FY22 Guidance Cut
Stanley Black & Decker, Inc. (NYSE:SWK) reported second-quarter FY22 revenue growth of 15.6% year-over-year to $4.39 billion, led by acquisitions…
American Tower Beats On Q2 Earnings; Cuts FY22 Property Revenue Growth Outlook Marginally
American Tower Corp (NYSE: AMT) reported second-quarter FY22 revenue growth of 16.3% year-on-year to $2.67 billion, beating the consensus of $2.64 billion.…
Keytruda, Gardasil Boost Merck’s Q2 Revenues, Tightens Annual Guidance
Merck & Co Inc’s (NYSE: MRK) Q2 sales reached $14.60 billion, +28% Y/Y, beating the consensus of $13.87 billion. Excluding the…
Labcorp To Spin Off Its Clinical Trial Business, Posts Mixed Q2 Earnings
Laboratory Corp of America Holdings (NYSE:LH) plans to spin off its unit focused on the clinical development business. Wall Street Journal was the…